 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Kiniksa Pharmaceuticals, Ltd. (KNSA) focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. 
Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
On November 1, KNSA reported 3rd Quarter September 2022 earnings of $0.67 per share on revenue of $99.1 million. The consensus earnings estimate was $0.38 per share on revenue of $113.0 million. Revenue grew 719.6% on a year-over-year basis.
Shares have formed a bullish "cup and handle" and higher share prices are expected.
Entry Point: $16.00
Trading Range: $7.36 to $16.78
Stop Loss: $15.20
Target Price: $17.60
